Physician profile
Robert B Pritt
NPI 1568424729
$6,995.16
in general payments reported to CMS, 2019-2025
33 companies · $750 in 2025
The $750 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $706 · 2021: $1,396 · 2022: $760 · 2023: $585 · 2024: $1,816 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,149.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,224.19 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $727.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $727.19 | 2021-2025 | |
| Lilly USA, LLC | $664.65 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $608.60 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $369.61 | 2019-2021 | |
| Amgen INC. | $297.67 | 2021-2024 | Repatha, Otezla |
| Pfizer INC. | $297.13 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $266.34 | 2019-2023 | Seglentis |
| Merck Sharp & Dohme LLC | $221.94 | 2019-2025 | Capvaxive, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $219.98 | 2019-2022 | |
| Allergan, INC. | $156.12 | 2019-2020 | |
| Spinal Simplicity, LLC | $149.89 | 2024 | Ha Minuteman G3-R |
| Boston Scientific Corporation | $141.89 | 2024 | |
| Biogen, INC. | $137.82 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $136.55 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $135.12 | 2021-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company Ltd. | $92.67 | 2022 | |
| Scilex Pharmaceuticals INC. | $60.08 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.65 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.89 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $40.64 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $34.22 | 2021 | |
| Nestle Healthcare Nutrition INC. | $30.85 | 2021 | |
| Reprise Biomedical, INC. | $28.38 | 2024 | Miro3d |
| Eisai INC. | $19.71 | 2021 | |
| Medicure Pharma INC. | $18.94 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.77 | 2019 | |
| Philips North America LLC | $17.18 | 2025 | Vest Therapy Und |
| Exact Sciences Corporation | $15.06 | 2023 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $13.78 | 2024 | |
| Azurity Pharmaceuticals, INC. | $13.39 | 2023 | Edarbi |
| Teva Pharmaceuticals USA, INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pritt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.